2 world-class ASX 50 shares to buy for your portfolio

Analysts are saying good things about these

| More on:
world's biggest companies represented by one person holding cityscape and another holding earth in hands

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ASX 50 index is where investors will find many of the highest quality companies that the Australian share market has to offer.

But which of these companies could be good options for investors right now? Let's take a look at two ASX 50 shares that analysts rate very highly:

CSL Limited (ASX: CSL)

The first ASX 50 share that we are going to look at is CSL.

It is one of the world's leading biotechnology companies, comprising the CSL Behring, CSL Vifor, and Seqirus businesses.

Over many decades, CSL has spent tens of billions on research and development (R&D) activities and acquisitions. This has led to the company owning a portfolio filled to the brim with high quality therapies and vaccines.

But management is never one to rest on its laurels. The company continues to invests 10%-11% of its sales revenue back into R&D each year. This means that CSL has a large number of potentially lucrative and life-saving therapies under development that will support its future growth.

The team at Citi has been bullish on CSL for some time and this remains the case today. Particularly given how recent industry commentary supports its view that immunoglobulin demand will grow strongly in the coming years. It said:

We attended Takeda's virtual Plasma-Derived Therapies (PDT) investor event. Takeda is expecting mid-to-high single digit volume growth for Immunoglobulin (Ig) over the medium-term despite the competition from FcRns – this is in-line with CSL's expectations and our forecasts.

Citi has a buy rating and $325.00 price target on its shares.

Telstra Corporation Ltd (ASX: TLS)

Another ASX 50 share that is highly rated by analysts is Telstra. It is of course Australia's largest telecommunications company.

Telstra went through a difficult period in the 2010s following the launch of the NBN. Pleasingly, that is all behind the company now and growth is back on the agenda thanks to the success of its T22 strategy and the launch of its successor – T25.

Commenting on the strategy, its CEO at the time, Andy Penn, said: "If T22 was a strategy of necessity, T25 is a strategy for growth."

Goldman Sachs appears to have confidence in the strategy based on its earnings growth forecasts. In addition, the broker highlights that this growth is low risk, which makes it even more appealing for investors. It said:

We believe the low risk earnings (and dividend) growth that Telstra is delivering across FY22-25, underpinned through its mobile business, is attractive. We also believe that Telstra has a meaningful medium term opportunity to crystallise value through commencing the process to monetize its InfraCo Fixed assets – which we estimate could be worth between A$22-33bn.

Goldman currently has a buy rating and $4.65 price target on Telstra's shares.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Happy man working on his laptop.
Blue Chip Shares

3 ASX blue chips to buy before earnings season

Analysts recently named these shares as buys. Let's see what they are recommending.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Blue Chip Shares

2 of the best ASX 200 blue chip shares to buy now

Bell Potter sees these as the creme de la creme right now.

Read more »

Person holding a blue chip.
Opinions

Buy alert! 2 ASX 200 blue-chip shares worth a look now: expert

Dylan Evans from Catapult Wealth has identified two blue-chip shares that he thinks are good buys today.

Read more »

A group of young friends celebrating and toasting with beers
Blue Chip Shares

This beaten-down ASX 200 stock could be a turnaround story

Let's see if analysts think this stock is a buy after its heavy decline.

Read more »

A young woman sits on a sofa in a stylish home with her laptop computer balanced on her knee and smiles with a satisfied look on her face at what she's seeing on the screen.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These stocks could provide strong passive income.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Blue Chip Shares

3 ASX 200 blue chip shares to buy with $3,000 in July

Analysts have recently named these well-known stocks as top buys.

Read more »

Two people having a meeting using a laptop and tablet to discuss Seven West Media's balance sheet
Blue Chip Shares

3 fantastic ASX shares to buy for an SMSF

Let's see why these shares that brokers rate as buys could be top picks for super investors.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Blue Chip Shares

Buy these fantastic ASX 200 blue chips with $10,000

Analysts think these top stocks are buys right now.

Read more »